Alpha’s Zunveyl approved for Alzheimer’s

The US Food and Drug Administration (FDA) has given its approval to Alpha Cognition’s (CSE: ACOG) oral therapeutic, Zunveyl (benzgalantamine), for the treatment of Alzheimer's disease (AD).

This marks the second oral AD therapy this decade to nab FDA approval. Zunveyl’s dual mechanism of action was designed to eliminate drug absorption in the gastrointestinal (GI) tract, potentially addressing certain tolerability issues with leading AD medications, combined with a long-term efficacy profile.

Zunveyl, a prodrug of AD treatment galantamine and an acetylcholinesterase inhibitor, is postulated to exert its therapeutic effect by preventing the breakdown of acetylcholine, the important brain neurotransmitter involved in memory, motivation, and attention functions.